Ertugliflozin for treatment of patients with Type 2 diabetes mellitus

Expert Review of Clinical Pharmacology
Junyi Yang

Abstract

Type 2 diabetes mellitus (T2DM) is a growing and serious global health problem. Inhibition of the sodium--glucosecotransporter-2 (SGLT2) can increase urinary glucose excretion and decrease plasma glucose levels in an insulin-independent manner. Ertugliflozin is a highly selective inhibitor of SGLT2, and was approved in the US for the treatment of adults with T2DM. Areas covered: In this paper, the mechanism of action, pharmacokinetics, clinical efficacy, safety, etc., of ertugliflozin have been introduced. Expert commentary: Ertugliflozin offers a novel, therapeutic approach to T2DM. Advantages of ertugliflozin include reduction in glycated hemoglobin, weight loss and blood pressure lowering with a low risk of hypoglycemia. The main adverse effects likely to be seen are genital fungal infections. Studies show that there is no increased risk of cardiovascular disease, but studies focusing on longer duration outcome are still essential.

References

Dec 6, 2006·The New England Journal of Medicine·Steven E KahnUNKNOWN ADOPT Study Group
Dec 10, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·M ObermeierW G Humphreys
Jun 16, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·J E Gerich
Apr 13, 2011·Diabetes/metabolism Research and Reviews·Vanita R Aroda, Robert Ratner
May 6, 2011·Journal of Clinical Pharmacology·Raktim Kumar GhoshSarfaraz Abdeli Jasdanwala
Oct 1, 2011·Diabetes, Obesity & Metabolism·R A DeFronzoS Del Prato
Nov 22, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Zhuang MiaoAmit S Kalgutkar
Mar 8, 2013·Diabetes, Obesity & Metabolism·J-F YaleG Meininger
Sep 24, 2014·Drug Design, Development and Therapy·Michael A Nauck
Oct 26, 2016·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·M Rizzi, R Trevisan
Oct 30, 2016·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Ranjeet Prasad DashNuggehally R Srinivas
Dec 13, 2016·Nature Reviews. Nephrology·Ralph A DeFronzoMuhammad Abdul-Ghani
Jan 17, 2017·Current Pharmaceutical Design·Niki KatsikiMichael J Theodorakis
Apr 19, 2017·Diabetes, Obesity & Metabolism·Anna SoliniEle Ferrannini
Nov 22, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·George GrunbergerBrett Lauring
Dec 29, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Priscilla HollanderBrett Lauring
Jan 10, 2018·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sam MillerBrett Lauring
Feb 22, 2018·Drugs·A Markham
Feb 28, 2018·Current Drug Safety·Mahakpreet Singh, Anoop Kumar

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.